Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case (scientific article published on 19 October 2017)

Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias

Q42699490

[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Q42712929

PET imaging of herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk reporter gene expression in mice and humans using [18F]FHBG.

Q45405582

Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration

Q46936274

[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging

Q47694602

Positron emission tomography imaging of tau pathology in progressive supranuclear palsy

Q47809826

18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome

Q47944653

Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies

Q48389127

Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy

Q48440202

Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy

Q48486327

[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration

Q48505309

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

Q48567985

Tau PET in Alzheimer disease and mild cognitive impairment.

Q48648902

In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography.

Q48687926

The Mini-Mental State Examination.

Q52095099

A new clinical scale for the staging of dementia.

Q52220854

Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy.

Q54737738

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop.

Q55042329

18 F-AV-1451 binds to putamen in multiple system atrophy

Q88790079

Neuropathological stageing of Alzheimer-related changes

Q27860862

Cortical Surface-Based Analysis

Q28124697

FreeSurfer

Q28124699

Staging of brain pathology related to sporadic Parkinson's disease

Q28131702

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Q29614948

Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system

Q29614989

Cerebral [18 F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy

Q30275833

Tauopathy PET and amyloid PET in the diagnosis of chronic traumatic encephalopathies: studies of a retired NFL player and of a man with FTD and a severe head injury.

Q30409615

Neuropathologic substrates of Parkinson disease dementia

Q30527797

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

Q30833019

Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration

Q33685317

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease

Q34526181

National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

Q34635272

Tau positron emission tomographic imaging in aging and early Alzheimer disease

Q36535275

Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue

Q36987267

An autoradiographic evaluation of AV-1451 Tau PET in dementia

Q37001820

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers

Q37198563

AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies

Q37633577

Pharmacokinetic Evaluation of the Tau PET Radiotracer 18F-T807 (18F-AV-1451) in Human Subjects.

Q37677783

Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

Q37739881

18F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy.

Q38404963

Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Q39021126

Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects.

Q39138168

Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases

Q39365272

Reference Tissue-Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging.

Q39429271

In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.

Q39758264

Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease

Q39789765

Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases

Q40364232

P433

issue

P921

main subject

Parkinson's disease

lessons learned

autopsy

page(s)

publication date

2017-10-19

P1433

published in

Acta Neuropathologica Communications

Q27724912

P1476

title

Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case

P478

volume

Reverse relations

cites work (P2860)

Q88246758	A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date
Q64245708	A walk through tau therapeutic strategies
Q94591997	APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline
Q54982491	Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
Q64952063	Biomarkers for tau pathology.
Q64252972	Clinical Imaging of Choroid Plexus in Health and in Brain Disorders: A Mini-Review
Q49987358	Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies
Q58099840	Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [F]Flortaucipir PET
Q92402592	Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span
Q91635608	Functional connectivity associated with tau levels in ageing, Alzheimer's, and small vessel disease
Q91961758	Hippocampal [18F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships
Q54942198	Increased Uptake of AV-1451 in a Subacute Infarction Lesion.
Q55031324	Molecular imaging: What is right and what is an illusion?
Q52592689	Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease.
Q93101629	Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
Q47869824	Spread of tau deposits: can we trust in vivo findings?
Q91011085	Tau PET imaging in neurodegenerative tauopathies-still a challenge
Q92221490	Tau and atrophy: domain-specific relationships with cognition
Q64109964	The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory
Q57635735	What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective
Q90173686	[18F]-AV-1451 tau PET imaging in Alzheimer's disease and suspected non-AD tauopathies using a late acquisition time window